Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma |
Newly Diagnosed and Recurrent Glioblastoma | Phase1 | France Germany Israel Italy Portugal Spain United Kingdom United States View all |
NCT05739942 |
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer |
Metastatic Castration Resistant Prostate Cancer | Germany | NCT06517719 | |
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. |
C3G | Phase3 | Brazil Canada China France Germany Greece India Israel Italy Japan Netherlands Spain Switzerland Turkey (Türkiye) United Kingdom United States View all |
NCT04817618 |
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis |
Multiple Sclerosis | Germany | NCT06551519 | |
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) |
Systemic Lupus Erythematosus | Phase3 | Argentina Brazil Bulgaria Canada China Colombia Czechia Guatemala Hungary Israel Japan Poland Portugal Singapore Slovakia South Africa Spain Thailand Turkey (Türkiye) United States View all |
NCT05639114 |
A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura® |
Asthma | South Korea | NCT05217810 | |
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
Oligometastatic Prostate Cancer (OMPC) | Phase3 | Argentina Australia Belgium Brazil Canada China Czechia France Germany Greece Hungary Israel Italy Japan Malaysia Mexico Netherlands Puerto Rico Singapore Slovakia Spain Switzerland Taiwan United Kingdom United States View all |
NCT05939414 |
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) |
Systemic Lupus Erythematosus | Phase3 | Argentina Australia Chile Colombia France Germany India Italy Malaysia Mexico Romania South Korea Taiwan United Kingdom United States View all |
NCT05624749 |
A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia |
HR+HER2- Advanced Breast Cancer | Russia | NCT06148506 | |
Dabrafenib and/or Trametinib Rollover Study |
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma | Phase4 | Spain United States |
NCT03340506 |